Uncategorized
Lampalizumab offers realistic hope for atrophic AMD
Lampalizumab may offer hope for people affected by atrophic age-related macular degeneration. Phase 3 trials are ongoing, and research is focusing on identifying patients who may better respond to the treatment.“We should be grateful for every small step forward, as atrophic AMD is the most difficult form of the disease. In wet AMD we treat to destroy something abnormal, while here we are trying to move forward the internal clock of cells that are programmed to die, which is an infinitely greater challenge,” Jordi Monés, MD, PhD, said in an (Read more...)